Trending...
- VENUS Goes Live on CATEX Exchange As UK Financial Ltd Activates The Premier Division Of The Maya Meme's League
- National Expansion Ignited Across Amazon $AMZN, Chewy $CHWY & Walmart $WMT: NDT Pharmaceuticals, Inc. (Stock Symbol: NDTP) $NDTP
- Dr. Sheel Desai Solomon and Preston Dermatology Continue Awards Streak with Top Honors in 2026 Maggy Awards
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023.
Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET
The fireside chat will be available via a live webcast accessible on Precision's website in the Investors section under Events & Presentations on February 28, 2023: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.
More on ncarol.com
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple ex vivo "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
Contacts
Investor Contact:
Mei Burris
Director, Investor Relations & Finance
Mei.burris@precisionbiosciences.com
Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET
The fireside chat will be available via a live webcast accessible on Precision's website in the Investors section under Events & Presentations on February 28, 2023: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.
More on ncarol.com
- Danholm Collection Launches Boutique Luxury Real Estate Brokerage in Central Florida
- Sellvia Market Expands Curated Store Portfolio for Dropshipping Sellers
- Food Journal Magazine Raises the Standard for Restaurant Reviews in Los Angeles
- Call for Nominations for the 2027 Paul E Garber First Flight Shrine
- Williamsville Spa Expands Team to Meet Growing Demand for Professional Facials
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple ex vivo "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
Contacts
Investor Contact:
Mei Burris
Director, Investor Relations & Finance
Mei.burris@precisionbiosciences.com
Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
Filed Under: Business
0 Comments
Latest on ncarol.com
- Lighthouse Tech Awards Recognize Top HR Technology Providers for 2026
- ADB Selects OneVizion to Advance Field Execution and Infrastructure Program Management
- Memelinked Social Media powered by cryptocurrency launching July 2026
- DwellSafe and Bruno Partner to Bring Clinician-Backed Stairlift Education to Families
- Seven-Year-Old Toronto Dancer Julianna Selivanov Wins Nine Medals at Quebec Championship and Reaches Finals at UK Dance Festival
- Leoforce Releases Beyond Programmatic: A Practical Guide to Long-Term Hiring Outcomes
- Progressive Dental & The Closing Institute Partner with Zest Dental Solutions to Elevate Full-Arch Growth and Patient Outcomes
- Spring Surge in 55+ Communities: What Buyers and Sellers Need to Know in 2026
- Jason Caras Launches The Caras Institute Following Successful Exit from IT Authorities
- Serina Damesworth Hired as Century Fasteners Corp. – Director of Quality
- National Expansion Ignited Across Amazon $AMZN, Chewy $CHWY & Walmart $WMT: NDT Pharmaceuticals, Inc. (Stock Symbol: NDTP) $NDTP
- Distributed Social Media - Own Your Content
- Tarrytown Expocare Pharmacy Announces Strategic Leadership Appointments to Accelerate Growth and Innovation
- New Environmental Thriller "The Star Thrower" Reimagines a Classic Lesson in Individual Impact
- Summit Appoints Javier Cabeza as Data, AI, and Analytics Practice Lead
- Interview: Why I Sponsored Carson Ware - The Full Story
- March Is Skiing's Smartest Buying Window
- Zeo Health Introduces KidZ Cleanse with Folinic Acid
- Cancun Airport Transportation Expands Fleet Ahead of Record Passenger Growth at Cancun International Airport
- Tobu Group's "T-home Series" of Accommodations in Tokyo Just Opened "T-home KEI."